NASDAQ:ALBO Albireo Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $21.13 +1.27 (+6.39%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$19.51▼$21.2850-Day Range$18.54▼$33.8952-Week Range$17.81▼$37.86Volume305,751 shsAverage Volume265,333 shsMarket Capitalization$409.08 millionP/E RatioN/ADividend YieldN/APrice Target$72.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Albireo Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside243.9% Upside$72.67 Price TargetShort InterestBearish17.06% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.67Based on 6 Articles This WeekInsider TradingSelling Shares$56.26 K Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.53) to ($4.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.17 out of 5 starsMedical Sector300th out of 1,412 stocksPharmaceutical Preparations Industry137th out of 673 stocks 3.5 Analyst's Opinion Consensus RatingAlbireo Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $72.67, Albireo Pharma has a forecasted upside of 243.9% from its current price of $21.13.Amount of Analyst CoverageAlbireo Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.06% of the float of Albireo Pharma has been sold short.Short Interest Ratio / Days to CoverAlbireo Pharma has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Albireo Pharma has recently increased by 35.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlbireo Pharma does not currently pay a dividend.Dividend GrowthAlbireo Pharma does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlbireo Pharma has received a 59.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Liver-disease medication (A05)", and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Albireo Pharma is -1.57. Previous Next 2.0 News and Social Media Coverage News SentimentAlbireo Pharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Albireo Pharma this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ALBO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Albireo Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Albireo Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,258.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Albireo Pharma is held by insiders.Percentage Held by Institutions82.99% of the stock of Albireo Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Albireo Pharma are expected to grow in the coming year, from ($6.53) to ($4.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Albireo Pharma is -12.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Albireo Pharma is -12.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlbireo Pharma has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About Albireo Pharma (NASDAQ:ALBO) StockAlbireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.Read More ALBO Stock News HeadlinesJune 30, 2022 | finance.yahoo.comAlbireo to Present at the William Blair Biotech Focus Conference 2022June 28, 2022 | finance.yahoo.comAlbireo Pharma, Inc. (NASDAQ:ALBO): When Will It Breakeven?June 23, 2022 | finance.yahoo.comAlbireo Announces Presentation of New Data in Pediatric and Adult Liver DiseasesJune 8, 2022 | finance.yahoo.comAlbireo to Present New Data at the EASL International Liver Congress™ 2022June 7, 2022 | finance.yahoo.comAlbireo to Present New Data at the 54th Annual Meeting of ESPGHANJune 2, 2022 | finance.yahoo.comAlbireo to Participate at Upcoming Investor ConferencesMay 23, 2022 | finance.yahoo.comAlbireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022May 21, 2022 | finance.yahoo.comTime To Worry? Analysts Are Downgrading Their Albireo Pharma, Inc. (NASDAQ:ALBO) OutlookMay 19, 2022 | finance.yahoo.comAlbireo to Participate in the H.C. Wainwright Global Investment Conference 2022May 17, 2022 | seekingalpha.comAlbireo stock plunges on disappointing Q1 resultMay 17, 2022 | seekingalpha.comAlbireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | finance.yahoo.comAlbireo Reports Q1 2022 Financial Results and Business UpdateMay 15, 2022 | finance.yahoo.comHere's What Albireo Pharma, Inc.'s (NASDAQ:ALBO) Shareholder Ownership Structure Looks LikeMay 13, 2022 | seekingalpha.comAlbireo Pharma Q1 2022 Earnings PreviewMay 13, 2022 | benzinga.comAlbireo Pharma's Earnings OutlookMay 9, 2022 | finance.yahoo.comAlbireo to Report Q1 2022 Financial Results on May 16May 7, 2022 | theglobeandmail.comInstrument Name Albireo Pharma Inc Instrument Symbol (ALBO-Q)May 4, 2022 | seekingalpha.comAlbireo: A Speculative Play With UpsideApril 19, 2022 | finance.yahoo.comInvesting in Albireo Pharma (NASDAQ:ALBO) five years ago would have delivered you a 57% gainMarch 29, 2022 | finance.yahoo.comAlbireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille SyndromeMarch 5, 2022 | finance.yahoo.comHere's Why Albireo Pharma (NASDAQ:ALBO) Can Manage Its Debt Despite Losing MoneyMarch 2, 2022 | seekingalpha.comAlbireo Pharma GAAP EPS of -$0.57, revenue of $32.52MMarch 1, 2022 | finance.yahoo.comAlbireo Reports Q4 and Year-End 2021 Financial Results and Business UpdateMarch 1, 2022 | finance.yahoo.comAlbireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue EstimatesFebruary 28, 2022 | seekingalpha.comAlbireo Pharma Q4 2021 Earnings PreviewSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALBO CUSIPN/A CIK1322505 Webwww.albireopharma.com Phone(857) 254-5555Fax203-796-5001Employees130Year Founded2003Company Calendar Last Earnings5/16/2022Today7/03/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$72.67 High Stock Price Forecast$80.00 Low Stock Price Forecast$66.00 Forecasted Upside/Downside+243.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34.03 million Net Margins-72.02% Pretax Margin-72.02% Return on Equity-73.93% Return on Assets-42.40% Debt Debt-to-Equity Ratio0.07 Current Ratio7.26 Quick Ratio7.20 Sales & Book Value Annual Sales$40.58 million Price / Sales10.08 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book2.32Miscellaneous Outstanding Shares19,360,000Free Float18,394,000Market Cap$409.08 million OptionableOptionable Beta0.92 Social Links Albireo Pharma Frequently Asked Questions Should I buy or sell Albireo Pharma stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Albireo Pharma stock. View analyst ratings for Albireo Pharma or view top-rated stocks. What is Albireo Pharma's stock price forecast for 2022? 3 Wall Street analysts have issued 12 month target prices for Albireo Pharma's shares. Their ALBO stock forecasts range from $66.00 to $80.00. On average, they anticipate Albireo Pharma's stock price to reach $72.67 in the next twelve months. This suggests a possible upside of 243.9% from the stock's current price. View analysts' price targets for Albireo Pharma or view top-rated stocks among Wall Street analysts. How has Albireo Pharma's stock performed in 2022? Albireo Pharma's stock was trading at $23.29 on January 1st, 2022. Since then, ALBO stock has decreased by 9.3% and is now trading at $21.13. View the best growth stocks for 2022 here. When is Albireo Pharma's next earnings date? Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Albireo Pharma. How were Albireo Pharma's earnings last quarter? Albireo Pharma, Inc. (NASDAQ:ALBO) posted its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($2.02) by $0.17. Albireo Pharma had a negative trailing twelve-month return on equity of 73.93% and a negative net margin of 72.02%. During the same period last year, the firm posted ($2.29) EPS. View Albireo Pharma's earnings history. Who are Albireo Pharma's key executives? Albireo Pharma's management team includes the following people: Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 59, Pay $1.1M)Mr. Simon Nicolas Reade Harford, CFO & Treasurer (Age 61, Pay $687.78k)Ms. Martha J. Carter, Chief Regulatory Officer (Age 70, Pay $710.69k)Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.Dr. Jan P. Mattsson Ph.D., Chief Scientific Officer, MD (Sweden) & Co-Founder (Age 58)Ms. Joan Connolly, Chief Technology OfficerMr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 48) (LinkedIn Profile)Ms. Michelle Graham, Chief HR Officer (Age 55)Dr. Kristina Torfgard, VP & Global Project HeadMs. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 54) (LinkedIn Profile) Who are some of Albireo Pharma's key competitors? Some companies that are related to Albireo Pharma include Xenon Pharmaceuticals (XENE), Aurinia Pharmaceuticals (AUPH), Emergent BioSolutions (EBS), Travere Therapeutics (TVTX), Axsome Therapeutics (AXSM), Supernus Pharmaceuticals (SUPN), Cryoport (CYRX), Ligand Pharmaceuticals (LGND), BELLUS Health (BLUSF), Lyell Immunopharma (LYEL), BridgeBio Pharma (BBIO), Day One Biopharmaceuticals (DAWN), Taro Pharmaceutical Industries (TARO), Zentalis Pharmaceuticals (ZNTL) and Sierra Oncology (SRRA). View all of ALBO's competitors. What other stocks do shareholders of Albireo Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE). What is Albireo Pharma's stock symbol? Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO." How do I buy shares of Albireo Pharma? Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Albireo Pharma's stock price today? One share of ALBO stock can currently be purchased for approximately $21.13. How much money does Albireo Pharma make? Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $409.08 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34.03 million in net income (profit) each year or ($1.76) on an earnings per share basis. How many employees does Albireo Pharma have? Albireo Pharma employs 130 workers across the globe. When was Albireo Pharma founded? Albireo Pharma was founded in 2003. How can I contact Albireo Pharma? Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for Albireo Pharma is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001. This page (NASDAQ:ALBO) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
